Overview

Nebulized Ketamine for the Treatment of Major Depressive Disorder in an Inpatient Setting

Status:
RECRUITING
Trial end date:
2026-09-30
Target enrollment:
Participant gender:
Summary
This is a double blind active placebo controlled clinical trial for individuals within an inpatient setting with moderate to severe depression. The purpose of this study is to assess if nebulized ketamine can reduce depressive symptoms.
Phase:
PHASE3
Details
Lead Sponsor:
Theresa Jacob, PhD, MPH
Treatments:
Ketamine